Cargando…

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors

BACKGROUND: Clinical trials based on FGFR mutation or amplification as a druggable target of FGFR inhibitors have produced disappointing clinical outcomes. Therefore, the identification of predictive biomarkers for FGFR-targeted agents has remained a crucial issue. METHODS: Expression profiles of FG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuan, Wu, Long, Tao, Weiping, Wu, Dawei, Ma, Fei, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293733/ https://www.ncbi.nlm.nih.gov/pubmed/32596330 http://dx.doi.org/10.1155/2020/5658904

Ejemplares similares

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

FGF/FGFR signaling in health and disease
por: Xie, Yangli, et al.
Publicado: (2020)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients
por: Zuo, Wei, et al.
Publicado: (2020)

Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis
por: Wu, Xinle, et al.
Publicado: (2009)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
por: Raja, Aroosha, et al.
Publicado: (2019)

Osteocyte-Specific Deletion of Fgfr1 Suppresses FGF23
por: Xiao, Zhousheng, et al.
Publicado: (2014)

FGF/FGFR signaling pathway involved resistance in various cancer types
por: Zhou, Yangyang, et al.
Publicado: (2020)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

Inhibition of FGFR Signaling by Targeting FGF/FGFR Extracellular Interactions: Towards the Comprehension of the Molecular Mechanism through NMR Approaches
por: Pagano, Katiuscia, et al.
Publicado: (2022)

FGF /FGFR Signal Induces Trachea Extension in the Drosophila Visual System
por: Chu, Wei-Chen, et al.
Publicado: (2013)

A Network Map of FGF-1/FGFR Signaling System
por: Raju, Rajesh, et al.
Publicado: (2014)

The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor
por: Astolfi, Annalisa, et al.
Publicado: (2020)

FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models
por: Rajendran, Ranjithkumar, et al.
Publicado: (2021)

Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation
por: Wiedlocha, Antoni, et al.
Publicado: (2021)

Targeting the FGF/FGFR axis and its co-alteration allies
por: Uehara, Y., et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
por: Furugaki, Koh, et al.
Publicado: (2023)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Dual roles of endothelial FGF-2–FGFR1–PDGF-BB and perivascular FGF-2–FGFR2–PDGFRβ signaling pathways in tumor vascular remodeling
por: Hosaka, Kayoko, et al.
Publicado: (2018)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer
por: Li, Li, et al.
Publicado: (2018)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

Targeted sequencing in FGF/FGFR genes and association analysis of variants for mandibular prognathism
por: Xiong, Xueyan, et al.
Publicado: (2017)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
por: Subbiah, Vivek, et al.
Publicado: (2023)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
por: Santolla, Maria Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v1koktkvatpm7gv59vfus1vtcr